A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion
Jeffrey G. Supko(Harvard University), Joseph P. Eder(Yale Cancer Center), Raja Velagapudi, Thomas J. Lynch(Nationwide Children's Hospital), Lee F. Allen(AMAG Pharmaceuticals (United States)), Jeffrey W. Clark(Massachusetts General Hospital), Donald Küfe(Dana-Farber Cancer Institute), Robert J. Fram
Cited by 30
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells
|New England Journal of Medicine|2008|1.6k